Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
March 2019
in “
Drugs - Real World Outcomes
”
Studysummary This study reported that while general patient characteristics and adverse event incidence for eribulin were comparable between a healthcare claims database and post-marketing surveillance, significant differences in some side effects such as neutropenia were observed.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on link.springer.com →